[
  {
    "ts": null,
    "headline": "BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations",
    "summary": "BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales expectations.",
    "url": "https://finnhub.io/api/news?id=d05354d3ce04a759400c67e19c97b0ac869ac2c667f9f388e8e046812b5ed1dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746044858,
      "headline": "BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations",
      "id": 134166110,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales expectations.",
      "url": "https://finnhub.io/api/news?id=d05354d3ce04a759400c67e19c97b0ac869ac2c667f9f388e8e046812b5ed1dc"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Reports Q1 Earnings, Reaffirms 2025 Revenue Guidance at US$61-64 Billion",
    "summary": "Pfizer (NYSE:PFE) reported a decline in its Q1 2025 earnings, with revenue dropping from the previous year, alongside stagnant share buyback activities. Despite reaffirming revenue guidance for 2025, these developments set the tone for Pfizer's share price fluctuation last week. Additionally, the company announced a $0.43 dividend which was in line with prior payouts. Over the same period, broader market trends showed a rise of 5.2%. Pfizer's 5.59% price move aligns with market movements,...",
    "url": "https://finnhub.io/api/news?id=14b9c29f52c34c6af0ee54597e705a12b7df0130d9e2650acebe74aa74442b79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746034355,
      "headline": "Pfizer (NYSE:PFE) Reports Q1 Earnings, Reaffirms 2025 Revenue Guidance at US$61-64 Billion",
      "id": 134166111,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) reported a decline in its Q1 2025 earnings, with revenue dropping from the previous year, alongside stagnant share buyback activities. Despite reaffirming revenue guidance for 2025, these developments set the tone for Pfizer's share price fluctuation last week. Additionally, the company announced a $0.43 dividend which was in line with prior payouts. Over the same period, broader market trends showed a rise of 5.2%. Pfizer's 5.59% price move aligns with market movements,...",
      "url": "https://finnhub.io/api/news?id=14b9c29f52c34c6af0ee54597e705a12b7df0130d9e2650acebe74aa74442b79"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Apr 30, 2025",
    "summary": "Companies In The News Are: NUE, REGN, PYPL, PFE.",
    "url": "https://finnhub.io/api/news?id=7060ae31a7fe7dd77dd4514c70386e9673d0f6988bb7ad59c41db1a737ad9bea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746018600,
      "headline": "Company News for Apr 30, 2025",
      "id": 134166112,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Companies In The News Are: NUE, REGN, PYPL, PFE.",
      "url": "https://finnhub.io/api/news?id=7060ae31a7fe7dd77dd4514c70386e9673d0f6988bb7ad59c41db1a737ad9bea"
    }
  },
  {
    "ts": null,
    "headline": "Boost Your Portfolio With These 5 Low Price-to-Book Stocks",
    "summary": "The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, MD, PFE, STNE and SAN are some such stocks.",
    "url": "https://finnhub.io/api/news?id=f7a7f84aadba6f6ad423fe06d076c922772cdcd8bc079104658be9bde7d78f7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746018480,
      "headline": "Boost Your Portfolio With These 5 Low Price-to-Book Stocks",
      "id": 134166113,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, MD, PFE, STNE and SAN are some such stocks.",
      "url": "https://finnhub.io/api/news?id=f7a7f84aadba6f6ad423fe06d076c922772cdcd8bc079104658be9bde7d78f7f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag",
    "summary": "Pfizer ( NYSE:PFE ) First Quarter 2025 Results Key Financial Results Revenue: US$13.7b (down 7.8% from 1Q 2024). Net...",
    "url": "https://finnhub.io/api/news?id=613d83fe51fb78002392e761e65522ba959f1c3ef7e3ebe119bc5f36d809c85a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746016645,
      "headline": "Pfizer First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag",
      "id": 134166114,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer ( NYSE:PFE ) First Quarter 2025 Results Key Financial Results Revenue: US$13.7b (down 7.8% from 1Q 2024). Net...",
      "url": "https://finnhub.io/api/news?id=613d83fe51fb78002392e761e65522ba959f1c3ef7e3ebe119bc5f36d809c85a"
    }
  },
  {
    "ts": null,
    "headline": "BridgeBio sales of new heart drug outstrip expectations",
    "summary": "In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s market-leading drug.",
    "url": "https://finnhub.io/api/news?id=ca592a4e5e5b286e1396279cf25a0f1713bf0d410560d2ea5dabeedb82bd0b31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746011234,
      "headline": "BridgeBio sales of new heart drug outstrip expectations",
      "id": 134166115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s market-leading drug.",
      "url": "https://finnhub.io/api/news?id=ca592a4e5e5b286e1396279cf25a0f1713bf0d410560d2ea5dabeedb82bd0b31"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Crash: 3 Absurdly Cheap Stocks to Load Up on for the Long Haul",
    "summary": "Entering trading on Monday, the S&P 500 has declined around 6% since the start of the year.  Three stocks that are down over 10% this year and trading at low earnings multiples are Pfizer (NYSE: PFE), PayPal (NASDAQ: PYPL), and Builders FirstSource (NYSE: BLDR).  Investors haven't been all that bullish on Pfizer this year -- it's down 13% thus far in 2025.",
    "url": "https://finnhub.io/api/news?id=07961ceca890c0b363087c316e51f7bc791d58b998eaf5062b80b47525f59b7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746011100,
      "headline": "Stock Market Crash: 3 Absurdly Cheap Stocks to Load Up on for the Long Haul",
      "id": 134141741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Entering trading on Monday, the S&P 500 has declined around 6% since the start of the year.  Three stocks that are down over 10% this year and trading at low earnings multiples are Pfizer (NYSE: PFE), PayPal (NASDAQ: PYPL), and Builders FirstSource (NYSE: BLDR).  Investors haven't been all that bullish on Pfizer this year -- it's down 13% thus far in 2025.",
      "url": "https://finnhub.io/api/news?id=07961ceca890c0b363087c316e51f7bc791d58b998eaf5062b80b47525f59b7c"
    }
  },
  {
    "ts": null,
    "headline": "Market Rally at Risk as Tariffs Damage Spreads. And 5 Other Things to Know Today.",
    "summary": "Chinese exports show the impact of U.S trade war, Meta’s stand-alone AI app will compete with rivals, and more news to start your day.",
    "url": "https://finnhub.io/api/news?id=4f1c7ea01d6bd848dabed67cce72e5b1b39937242c52b839003103cc1bfd57ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746011040,
      "headline": "Market Rally at Risk as Tariffs Damage Spreads. And 5 Other Things to Know Today.",
      "id": 134166116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Chinese exports show the impact of U.S trade war, Meta’s stand-alone AI app will compete with rivals, and more news to start your day.",
      "url": "https://finnhub.io/api/news?id=4f1c7ea01d6bd848dabed67cce72e5b1b39937242c52b839003103cc1bfd57ed"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Dividend Yield Is 7.5%. Is It Still Safe?",
    "summary": "A high dividend yield can be enticing, but it can also raise flags for income investors.  Pfizer's falling valuation has pushed its yield up to well over 7%, which warrants a closer look.  The company's payout ratio and free cash flow can help investors assess the safety of the dividend.",
    "url": "https://finnhub.io/api/news?id=f2072183da4241864aeb8e66b1f7a491ed7e4151d246f6af39cc1debd1a48055",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746008100,
      "headline": "Pfizer's Dividend Yield Is 7.5%. Is It Still Safe?",
      "id": 134141742,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A high dividend yield can be enticing, but it can also raise flags for income investors.  Pfizer's falling valuation has pushed its yield up to well over 7%, which warrants a closer look.  The company's payout ratio and free cash flow can help investors assess the safety of the dividend.",
      "url": "https://finnhub.io/api/news?id=f2072183da4241864aeb8e66b1f7a491ed7e4151d246f6af39cc1debd1a48055"
    }
  },
  {
    "ts": null,
    "headline": "Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?",
    "summary": "Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer.  Pfizer should be able to easily fund an acquisition of either small drugmaker.  The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies.",
    "url": "https://finnhub.io/api/news?id=08438753e639671ed9d0d66c98e456fb79ed5f18e0cfc549c3594b05f0c35f71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746003060,
      "headline": "Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?",
      "id": 134141743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer.  Pfizer should be able to easily fund an acquisition of either small drugmaker.  The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies.",
      "url": "https://finnhub.io/api/news?id=08438753e639671ed9d0d66c98e456fb79ed5f18e0cfc549c3594b05f0c35f71"
    }
  },
  {
    "ts": null,
    "headline": "Is Healthcare Losing the Status of Safe Haven? ETFs in Focus",
    "summary": "Healthcare stocks face new risks under Trump, despite their usual defensive reputation.",
    "url": "https://finnhub.io/api/news?id=537fb8ae160bcb66ea96fa153b413a7e59f5772d30b1955d8863d7fbf78f17f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746001980,
      "headline": "Is Healthcare Losing the Status of Safe Haven? ETFs in Focus",
      "id": 134141744,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Healthcare stocks face new risks under Trump, despite their usual defensive reputation.",
      "url": "https://finnhub.io/api/news?id=537fb8ae160bcb66ea96fa153b413a7e59f5772d30b1955d8863d7fbf78f17f5"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain",
    "summary": "Both Pfizer and Viking aim to enter the high-growth weight loss drug market.  Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss.  Today, Eli Lilly and Novo Nordisk dominate with their well-known treatments: Lilly makes tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight loss.",
    "url": "https://finnhub.io/api/news?id=5b74bb774d947685f730fe20b847a6e3c89ce0cfd3b8ceb7d314036a56dc5ecc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745997300,
      "headline": "Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain",
      "id": 134141745,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Both Pfizer and Viking aim to enter the high-growth weight loss drug market.  Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss.  Today, Eli Lilly and Novo Nordisk dominate with their well-known treatments: Lilly makes tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight loss.",
      "url": "https://finnhub.io/api/news?id=5b74bb774d947685f730fe20b847a6e3c89ce0cfd3b8ceb7d314036a56dc5ecc"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc (PFE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline and Strategic Growth",
    "summary": "Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future success.",
    "url": "https://finnhub.io/api/news?id=41eafb885aa61bc2c834353a5d0495afa77b8f77b80360699b2e152206bfad99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745997116,
      "headline": "Pfizer Inc (PFE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline and Strategic Growth",
      "id": 134141746,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future success.",
      "url": "https://finnhub.io/api/news?id=41eafb885aa61bc2c834353a5d0495afa77b8f77b80360699b2e152206bfad99"
    }
  },
  {
    "ts": null,
    "headline": "Q1 2025 Pfizer Inc Earnings Call",
    "summary": "Q1 2025 Pfizer Inc Earnings Call",
    "url": "https://finnhub.io/api/news?id=fe5f12b427fd9b7d685df82bbe05cbf2d8fbbe9887329ec13e21c11cdaa8c49e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745996151,
      "headline": "Q1 2025 Pfizer Inc Earnings Call",
      "id": 134141747,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Q1 2025 Pfizer Inc Earnings Call",
      "url": "https://finnhub.io/api/news?id=fe5f12b427fd9b7d685df82bbe05cbf2d8fbbe9887329ec13e21c11cdaa8c49e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Q1 Update May Mark A Bottom In The Stock",
    "summary": "Pfizer is facing some revenue pressures due to some higher Medicare discounts. Read more to see why I upgrade PFE stock from sell to hold.",
    "url": "https://finnhub.io/api/news?id=188799c5d375ec2a1392f7ce774aaa67ccc8f7dd0b699c5ca0f01c8f1b8925ce",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745987060,
      "headline": "Pfizer's Q1 Update May Mark A Bottom In The Stock",
      "id": 134140443,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163791811/image_2163791811.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer is facing some revenue pressures due to some higher Medicare discounts. Read more to see why I upgrade PFE stock from sell to hold.",
      "url": "https://finnhub.io/api/news?id=188799c5d375ec2a1392f7ce774aaa67ccc8f7dd0b699c5ca0f01c8f1b8925ce"
    }
  },
  {
    "ts": null,
    "headline": "Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?",
    "summary": "Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.",
    "url": "https://finnhub.io/api/news?id=1edbec3f6019ba7435ca5a4c393a0e3d3aa94413faa1db6c124abd43a9fbe5ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745973120,
      "headline": "Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?",
      "id": 134141748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.",
      "url": "https://finnhub.io/api/news?id=1edbec3f6019ba7435ca5a4c393a0e3d3aa94413faa1db6c124abd43a9fbe5ac"
    }
  }
]